About Veracyte
Veracyte is a company based in San Francisco (United States) founded in 2008. Veracyte has raised $67.9 million across 6 funding rounds from investors including Kleiner Perkins, TPG and General Electric. The company has 824 employees as of December 31, 2024. Veracyte has completed 4 acquisitions, including Allegro Diagnostics, C2i Genomics and Decipher. Veracyte offers products and services including Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, and Decipher Bladder Genomic Classifier. Veracyte operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter San Francisco, United States
- Employees 824 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Veracyte, Inc.
-
Annual Revenue
$445.76 M (USD)23.46as on Dec 31, 2024
-
Net Profit
$24.14 M (USD)0as on Dec 31, 2024
-
EBITDA
$56.67 M (USD)274.69as on Dec 31, 2024
-
Total Equity Funding
$67.9 M (USD)
in 6 rounds
-
Latest Funding Round
$45 M (USD), Debt – Conventional
Mar 28, 2016
-
Investors
Kleiner Perkins
& 9 more
-
Employee Count
824
as on Dec 31, 2024
-
Investments & Acquisitions
Allegro Diagnostics
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Veracyte
Veracyte is a publicly listed company on the NASDAQ with ticker symbol VCYT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Veracyte
Veracyte offers a comprehensive portfolio of products and services, including Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, and Decipher Bladder Genomic Classifier.
Test for thyroid cancer diagnosis using genomic data.
Assists in prostate cancer prognosis and treatment decisions.
Evaluates breast cancer risk through genomic analysis.
Supports bladder cancer assessment with molecular insights.
People of Veracyte
Unlock access to complete
Unlock access to complete
Funding Insights of Veracyte
Veracyte has successfully raised a total of $67.9M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $45 million completed in March 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Veracyte
Veracyte has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Kleiner Perkins, TPG and General Electric.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment opportunities in healthcare are managed by Broadfin Capital.
|
Locked | Locked | Locked | |
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked |
Investor details for Veracyte
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Veracyte
Veracyte has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Allegro Diagnostics, C2i Genomics and Decipher.
Investment portfolio details for Veracyte
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Liquid biopsy for post-cancer surgery tumor monitoring is provided.
|
Locked | Locked | 2019 | Locked | |
|
Developer of diagnostic product for colon cancer
|
Locked | Locked | 2015 | Locked | |
|
Genomic test solutions for cancer diagnosis are developed.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for Veracyte
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Veracyte
Detailed financials for Veracyte
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Veracyte Comparisons
Peer comparison for Veracyte
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Veracyte
Veracyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Veracyte
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Veracyte
Complete news archive for Veracyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Veracyte
Veracyte was founded in 2008.
Veracyte is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Veracyte is a funded company, having raised a total of $67.9M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Veracyte is 824.
Annual revenue of Veracyte is $445.76M as on Dec 31, 2024.
Veracyte was founded in 2008 and is headquartered in San Francisco, United States. Genomics-based diagnostics for cancer are developed and offered by the company within the healthcare sector. Products such as the Percepta test are utilized to evaluate lung cancer risk through analysis of bronchial epithelial cells, while the Afirma Thyroid FNA Analysis identifies benign thyroid nodules. Additional tests, including the Envisia classifier for idiopathic pulmonary fibrosis, are under development.
Veracyte's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Veracyte offers Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, and Decipher Bladder Genomic Classifier.
Yes, Veracyte is publicly traded on NASDAQ under the ticker symbol VCYT.
Veracyte has made 4 acquisitions, including Allegro Diagnostics, C2i Genomics, and Decipher.
Veracyte has 10 investors. Key investors include Kleiner Perkins, TPG, General Electric, Camber Capital Management, and Broadfin Capital.
The ticker symbol of Veracyte is VCYT on NASDAQ.